Hengrui Medicine: HRS-4642 injection included in the list of breakthrough therapies.

Hengrui Medicine announced that its HRS-4642 injection has been included in the list of breakthrough therapies by the Drug Evaluation Center. The injection is a Class 1 chemical drug intended for first-line treatment of advanced or metastatic pancreatic cancer with the KRASG12D mutation, with an application submitted on December 24, 2025. It is a self-developed KRASG12D inhibitor by the company, with no similar drugs approved for marketing domestically or internationally. The total research and development investment in the related project is approximately 254 million yuan. Drug research and development are subject to various factors and uncertainties, and the company will continue to progress with the project and disclose updates.